Myasthenia Gravis Forecast in 26 Major Markets 2017-2027: One of the Most Significant Diseases Affecting the Neuromuscular Junction - Research and Markets
DUBLIN, April 20, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Myasthenia Gravis Forecast in 26 Major Markets 2017-2027" report to their offering.
Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases affecting the neuromuscular junction. The disorder is caused by auto-antibodies that target components of the post-synaptic muscle endplate. This includes antibodies that target acetylcholine receptors (AChR), muscle-specific kinase (MUSK) and lipoprotein release protein 4 (LRP4). Please note that this module does not cover congenital MG forms.
This report provides the current prevalent population for Myasthenia Gravis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Denmark, Netherlands, Norway, Sweden, Estonia, Croatia, Poland, Russia, Greece, Turkey, Japan, China, South Korea, Argentina, Brazil, Mexico, India and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Myasthenia Gravis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
MG often co-occurs with other autoimmune conditions including:
- RA
- MS
- Ankylosing spondylitis
- Psoriasis
- Sjogren's syndrome
- Ulcerative colitis
- Crohn's disease
- Other forms of AI
Reasons to Buy:
- Able to quantify patient populations in global Myasthenia Gravis market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of Myasthenia Gravis and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Myasthenia Gravis prevalent population.
- Identify sub-populations within Myasthenia Gravis which require treatment.
- Gain an understanding of the specific markets that have the largest number of Myasthenia Gravis patients.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions/Features Associated with the Disease
8. Methodology for quantification of patient numbers
9. Top-line Prevalence for Myasthenia Gravis
10. Classification of Myasthenia Gravis Patients
11. Abbreviations used in the report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
14. References
15. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/mhs3qg/myasthenia_gravis
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article